ATR 蛋白抑制剂全球市场：临床试验和市场机会洞察 (2024)

Global ATR Protein Inhibitors Clinical Trials & Market Opportunity Insight 2024

出版日期: 2023年11月01日 | 出版商:

KuicK Research | 英文 88 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

ATR 激□的抑制已成为不断发展的癌症药物研究的一个有前途的途径。 ATR 是一种丝胺酸/苏胺酸蛋白激□，在细胞对 DNA 损伤的反应中发挥重要作用，从而保护基因组完整性。 ATR 失调与多种疾病有关，尤其是癌症，抑制 ATR 为利用癌细胞的脆弱性和提高现有治疗的有效性提供了新的机会。目前，还没有 ATR 蛋白抑制剂获得监管部门的批准，但随着开发管道中的几个研究候选药物进入 II 期试验，这些新型抑制剂预计将受到更多关注。

ATR抑制的主要焦点是在肿瘤学领域。 ATR蛋白抑制剂有望增强损伤DNA的癌症治疗的有效性，如化疗和放疗，并有望提高损伤DNA的癌症治疗的有效性，如卵巢癌、胆管癌、乳腺癌、小细胞癌它是多种癌症类型联合治疗的候选药物，包括晚期实体瘤和一些血液恶性肿瘤。在这些癌症中正在研究的 ATR 候选抑制剂包括 ATG-018、Elimusertib (BAY1895344)、Camonsertib (RP-3500) 和 Ceralasertib (AZD6738)，分别由 Antengene、Bayer、Repair Therapeutics 和 AstraZeneca 开发。这些候选药物目前正处于临床评估的各个阶段。

与其他癌症治疗方法相比，ATR 蛋白抑制剂具有多种优势。如上所述，ATR 蛋白抑制剂有可能使癌细胞对常规治疗敏感，从而减少所需剂量并减少副作用。儘管传统疗法很有效，但也有一些限制。 ATR 抑制有助于克服癌细胞对治疗产生的抗药性机制，进而改善患者的治疗效果。此外，ATR 蛋白抑制剂透过针对患者特定的遗传弱点，实现更个人化的癌症治疗方法。在神经退化性疾病和病毒感染领域，ATR 抑制有望减缓或预防疾病进展并改善受影响个体的生活品质。

虽然 ATR 蛋白抑制剂的环境由于其优于现有治疗方法而乐观，但挑战也存在，包括需要改进患者分类标准和更好地了解潜在的副作用。Masu。然而，ATR蛋白抑制剂的未来潜力是巨大的。随着 ATR 蛋白抑制剂继续展现出前景，它们在联合疗法中的应用预计将变得更加普遍，并有可能重塑癌症治疗方案。此外，分子谱分析和基因检测的进步可能使 ATR 的抑制更有针对性。

本报告调查了全球 ATR 蛋白抑制剂市场，并提供了市场概况，包括药物趋势、临床试验趋势、区域趋势以及进入市场的公司竞争格局。

Inhibition of the Ataxia telangiectasia and Rad3 related kinase, or ATR kinase, has emerged as a promising avenue in the ever evolving landscape of cancer pharmaceutical research. ATR is a serine/threonine-protein kinase that acts as a guardian of genomic integrity by playing a critical role in the cellular response to DNA damage. Dysregulation of ATR has been linked to various diseases, particularly cancer, and inhibiting ATR presents a novel opportunity to exploit the vulnerabilities of cancer cells and enhance the efficacy of existing therapies. No ATR inhibitors have received regulatory approval as of yet; however, with several investigational candidates in the development pipeline now entering phase II trials, these novel inhibitors are anticipated to gain more attention in the years to come.

The primary focus of ATR inhibition is in the realm of oncology. ATR inhibitors have shown promise in enhancing the effectiveness of DNA-damaging cancer therapies such as chemotherapy and radiation, making hem potential candidates for combination therapies in various cancer types such as ovarian cancer, bile duct carcinoma, breast carcinoma, small cell cancer and high grade neuroendocrine cancers among other advanced solid tumors, as well as some hematological malignancies. Some ATR-inhibiting candidates being investigated in these cancers are ATG-018, Elimusertib (BAY 1895344), Camonsertib (RP-3500), and Ceralasertib (AZD6738), which have been developed by Antengene, Bayer, Repare Therapeutics, and AstraZeneca, respectively. These candidates are now in various phases of clinical evaluation.

Recent research, however, has expanded the scope of ATR inhibitors to neurodegenerative diseases. ATR kinase has implications in maintaining neuronal genomic activity, making it a potential target for conditions like Parkinson's disease and Alzheimer's disease. Further studies are linking ATR with microbial infections, especially those caused by viruses. Along with ATM, or Ataxia-telangiectasia mutated kinase, ATR is exploited by viruses to facilitate viral replication and increase expression of viral proteins. In the case of HIV-1 and COVID-19, both of which have high infection and mortality rates, ATR inhibition has represented another promising prospect for the development of novel therapeutics to manage these diseases.

As a result, the pharmaceutical industry has invested significantly in the development of ATR inhibition, and several clinical trials are being conducted now to evaluate the efficacy of these candidates. VE-821, developed by Vertex Pharmaceuticals, was the first specific ATR inhibitor to be developed, which served as the blueprint for the development of VE-822, now licensed to Merck as Berzosertib. The drug further served as the foundation for M1774, a potent ATR inhibitor being studied by Merck in various solid cancers. Both Berzosertib and M1774 have demonstrated encouraging results in early phase clinical trials in combination with chemotherapy. Administration of these ATR inhibitors enhanced the sensitivity of cancer cells to DNA-damaging chemotherapies, which makes the elimination of cancer cells faster.

ATR inhibitors pose several benefits over other cancer therapies. As described above, ATR inhibitors sensitize cancer cells to conventional therapies, potentially reducing the required dosage and mitigating side effects. Conventional therapies are potent but also face several limitations, majorly resistance to treatment. ATR inhibition can help overcome resistance mechanisms that cancer cells development against treatment, therefore improving patient outcomes. Further, ATR inhibitors can also enable a more personalized approach to cancer treatment by targeting specific genetic vulnerabilities in patients. In the realm of neurodegenerative diseases and viral infections, ATR inhibition holds the promise of slowing or preventing disease progression and improving the quality of life of affected individuals.

Despite the optimism surrounding ATR inhibitors as outlined by their advantages over existing therapies, challenges exist such as the need for refined patient section criteria and a deeper understanding of the potential side effects. However, their future potential is vast. As ATR inhibitors continue to show promise, their integration into combination therapies is expected to become more common, potentially reshaping cancer treatment regimens. Moreover, advances in molecular profiling and genetic testing may enable a more targeted ATR inhibition.

The ongoing clinical and market trends for ATR inhibitors present a compelling narrative in the pharmaceutical domain. The novel approach to targeting DNA damage response pathways holds the promise of revolutionizing cancer treatment, as well as entering the treatment protocols for neurodegenerative and infectious diseases. With ongoing research studies revealing more about ATR kinase and its implications in different indications, it is understood the full potential of ATR inhibition is yet to be realized. As this happens, a new wave of development in the global pharmaceutical market is anticipated, which makes the ATR inhibition an exciting field.

1. Introduction to ATR Inhibition

1.1. Overview of ATR Protein & ATR Inhibition
1.2. History & Evolution of ATR Inhibitors

2. ATR Inhibitors: Research & Clinical Trials Overview by Indication

2.1. Solid Cancers
2.2. Hematological Cancers

3. Global ATR Inhibitors Market Outlook

3.1. Current Market Trends & Developments
3.2. Future Growth Avenues

4. ATR Inhibitors Development Trends by Region

4.1. US
4.2. EU
4.3. UK
4.4. Canada
4.5. China
4.6. Japan
4.7. Australia

5. Global ATR Protein Inhibitors Clinical Trials Overview

5.1. By Country
5.2. Indication
5.3. Phase
5.4. Therapy Class

6. Global ATR Protein Inhibitors Clinical Pipeline By Company, Indication & Phase

6.1. Research
6.2. Preclinical
6.3. Phase-I
6.4. Phase-I/II
6.5. Phase-II
6.6. Phase-III

7. Global ATR Inhibitors Market Drivers & Challenges

7.1. Drivers & Opportunities
7.2. Challenges & Restraints

8. Competitive Landscape

8.1. Antengene Corporation
8.2. Aprea
8.3. AstraZeneca
8.4. Bayer
8.5. Beijing Tide Pharmaceutical
8.6. Biocity Biopharmaceutics
8.7. Chipscreen Biosciences
8.8. IMPACT Therapeutics
8.9. Laevoroc Neuro-Oncology
8.10. Repare Therapeutics
8.11. Shanghai De Novo Pharmatech
8.12. Shanghai Junshi Biosciences
8.13. ShangPharma
8.14. Vertex Pharmaceuticals

简介目录图表

List of Figures

Figure 1-1: ATR Mediated DNA Damage Repair Signaling
Figure 1-2: Benefits of ATR Inhibitors
Figure 1-3: ATR inhibitors in Clinical Trials
Figure 1-4: ATR Inhibitors - History & Evolution
Figure 2-1: LATIFY Phase III Study - Initiation & Completion Years
Figure 2-2: ATRiBRAVE Phase II Study - Initiation & Completion Years
Figure 2-3: DASH Phase II Study - Initiation & Completion Years
Figure 2-4: MATRiX Phase II Study - Initiation & Completion Years
Figure 2-5: NCI-2021-10751 Phase I/II Study - Initiation & Completion Years
Figure 2-6: ACE-CL-110 Phase I Study - Initiation & Completion Years
Figure 3-1: ATR inhibitors - Future Growth Avenues
Figure 5-1: Global - ATR Protein Inhibitors Clinical Trials by Country (Numbers), 2023 & 2024
Figure 5-2: Global - ATR Protein Inhibitors Clinical Trials by Indication (Numbers), 2023 & 2024
Figure 5-3: Global - ATR Protein Inhibitors Clinical Trials by Phase (Numbers), 2023 & 2024
Figure 5-4: Global - ATR Protein Inhibitors Clinical Trials by Therapy Class (Numbers), 2023 & 2024
Figure 7-1: ATR Inhibitors Market Drivers
Figure 7-2: ATR Inhibitors Market Challenges

List of Tables

Table 4-1: US - National Cancer Institute Sponsored Clinical Trials for ATR Inhibitors
Table 4-2: EU - Ongoing Clinical Trials for ATR Inhibitors
Table 4-3: UK - Ongoing Clinical Trials for ATR Inhibitors
Table 4-4: Canada - Ongoing Clinical Trials for ATR Inhibitors
Table 4-5: China - Ongoing Clinical Trials for ATR Inhibitors
Table 4-6: Japan - Ongoing Clinical Trials for ATR Inhibitor M1774
Table 4-7: Australia - Ongoing Clinical Trials for ATR Inhibitors

02-2729-4219

+886-2-2729-4219